JO
CRDL

John Overdeck’s Cardiol Therapeutics CRDL Stock Holding History

John Overdeck’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$792K Buy
746,937
+212,726
+40% +$269K ﹤0.01% 3795
2026
Q1 		$721K Buy
534,211
+127,276
+31% +$131K ﹤0.01% 3477
2025
Q4 		$388K Buy
406,935
+174,590
+75% +$183K ﹤0.01% 3449
2025
Q3 		$249K Buy
+232,345
New +$282K ﹤0.01% 3301
2024
Q4 		– Sell
-24,666
Closed -$48.8K – 3249
2024
Q3 		$48.8K Buy
+24,666
New +$51.2K ﹤0.01% 2971
2022
Q1 		– Sell
-194,554
Closed -$360K – 2987
2021
Q4 		$360K Buy
+194,554
New +$537K ﹤0.01% 3520

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

John Overdeck's CRDL Position: Q2 2026 in Review

John Overdeck increased its Cardiol Therapeutics (CRDL) stake by 40% in Q2 2026, buying an estimated $269K and bringing the position to 746,937 shares worth $792K. The position accounts for ﹤0.01% of the portfolio, ranked #3795.

John Overdeck first reported a position in CRDL in Q4 2021 and has held it in 6 quarters since. 52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • John Overdeck held 746,937 shares of Cardiol Therapeutics worth $792K as of Q2 2026.
  • John Overdeck bought 212,726 Cardiol Therapeutics shares in Q2 2026, an estimated $269K.
  • Cardiol Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3795 holding.
  • John Overdeck first reported a position in Cardiol Therapeutics in Q4 2021 and has held it in 6 quarters since.
  • 52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.